https://pdcurejourney.org/ https://pdcurejourney.org/a-z/ https://pdcurejourney.org/about/ https://pdcurejourney.org/approaches/beyond-the-brain/ https://pdcurejourney.org/approaches/clear-the-protein/ https://pdcurejourney.org/approaches/help-cells-clean-up/ https://pdcurejourney.org/approaches/inherited-causes/ https://pdcurejourney.org/approaches/protect-fragile-cells/ https://pdcurejourney.org/approaches/replace-or-repair/ https://pdcurejourney.org/coming-next/ https://pdcurejourney.org/glossary/ https://pdcurejourney.org/join-a-trial/ https://pdcurejourney.org/landmarks/1-dopamine-missing-1960/ https://pdcurejourney.org/landmarks/10-stem-cell-dopamine-neurons-2025/ https://pdcurejourney.org/landmarks/100-tfeb-lysosome-biogenesis-2013/ https://pdcurejourney.org/landmarks/101-exenatide-pilot-2013/ https://pdcurejourney.org/landmarks/102-coq10-phase2-2002/ https://pdcurejourney.org/landmarks/103-synuclein-vaccines-2005-2026/ https://pdcurejourney.org/landmarks/104-exercise-sparx-sparx3-2017-2026/ https://pdcurejourney.org/landmarks/105-pioglitazone-fs-zone-2015/ https://pdcurejourney.org/landmarks/106-simvastatin-pd-stat-2022/ https://pdcurejourney.org/landmarks/107-gm1-ganglioside-2012/ https://pdcurejourney.org/landmarks/108-buntanetap-phase3-2024/ https://pdcurejourney.org/landmarks/109-gba-gene-therapy-pr001-2020-2026/ https://pdcurejourney.org/landmarks/11-complex-i-deficiency-1989/ https://pdcurejourney.org/landmarks/110-biib094-lrrk2-antisense-2026/ https://pdcurejourney.org/landmarks/111-aav-php-b-brain-capsids-2016-2024/ https://pdcurejourney.org/landmarks/112-aav-aadc-gene-therapy-2009-2024/ https://pdcurejourney.org/landmarks/113-prosavin-oxb-102-lentiviral-gene-therapy-2014-2026/ https://pdcurejourney.org/landmarks/114-mds-updrs-2008/ https://pdcurejourney.org/landmarks/115-neurofilament-light-progression-2020/ https://pdcurejourney.org/landmarks/116-synuclein-pet-tracers-2023-2025/ https://pdcurejourney.org/landmarks/117-snca-gene-editing-2018-2023/ https://pdcurejourney.org/landmarks/118-ema-pd-guideline-two-step-2008-2025/ https://pdcurejourney.org/landmarks/119-linked-clinical-trials-2013/ https://pdcurejourney.org/landmarks/12-parkin-gene-1998/ https://pdcurejourney.org/landmarks/120-mobilise-d-digital-mobility-2020/ https://pdcurejourney.org/landmarks/121-fbxo7-pla2g6-recessive-parkinsonism-2008-2013/ https://pdcurejourney.org/landmarks/122-rab39b-x-linked-parkinsonism-2014/ https://pdcurejourney.org/landmarks/123-vps13c-recessive-parkinsonism-2016/ https://pdcurejourney.org/landmarks/124-multi-ancestry-gwas-2023-2024/ https://pdcurejourney.org/landmarks/125-mapt-tau-risk-locus-2009/ https://pdcurejourney.org/landmarks/126-mitochondrial-derived-vesicles-2012-2016/ https://pdcurejourney.org/landmarks/128-neuromelanin-and-iron-in-the-nigra-1988-2019/ https://pdcurejourney.org/landmarks/129-glutathione-loss-nigra-1994/ https://pdcurejourney.org/landmarks/13-rotenone-model-2000/ https://pdcurejourney.org/landmarks/130-body-first-brain-first-subtypes-2019-2020/ https://pdcurejourney.org/landmarks/131-urate-epidemiology-2007-2008/ https://pdcurejourney.org/landmarks/132-sex-differences-risk-2004/ https://pdcurejourney.org/landmarks/133-air-pollution-parkinsons-2019-2023/ https://pdcurejourney.org/landmarks/134-skin-biopsy-synuclein-2024/ https://pdcurejourney.org/landmarks/135-pdbp-biofind-2012-2016/ https://pdcurejourney.org/landmarks/136-uk-brain-bank-criteria-1992/ https://pdcurejourney.org/landmarks/137-23andme-ukbiobank-cohorts-2019-2020/ https://pdcurejourney.org/landmarks/138-ml-synuclein-aggregation-inhibitors-2024/ https://pdcurejourney.org/landmarks/139-fmt-trials-2024/ https://pdcurejourney.org/landmarks/14-snca-triplication-2003/ https://pdcurejourney.org/landmarks/140-earlystim-2013/ https://pdcurejourney.org/landmarks/141-lixisenatide-lixipark-2024/ https://pdcurejourney.org/landmarks/142-exenatide-phase3-pd3-2025/ https://pdcurejourney.org/landmarks/143-nly01-phase2-2023/ https://pdcurejourney.org/landmarks/144-isradipine-steady-pd3-2020/ https://pdcurejourney.org/landmarks/145-biib122-luma-2026/ https://pdcurejourney.org/landmarks/146-gdnf-infusion-trials-2006-2019/ https://pdcurejourney.org/landmarks/147-cere-120-neurturin-2010-2015/ https://pdcurejourney.org/landmarks/149-nurr1-agonists-2015-2024/ https://pdcurejourney.org/landmarks/15-pink1-and-mitophagy-2004/ https://pdcurejourney.org/landmarks/150-udca-up-study-2023/ https://pdcurejourney.org/landmarks/151-focused-ultrasound-bbb-opening-2018-2022/ https://pdcurejourney.org/landmarks/152-cdnf-phase1-2-2017-2023/ https://pdcurejourney.org/landmarks/153-anle138b-oligomer-modulator-2019-2026/ https://pdcurejourney.org/landmarks/154-sargramostim-gm-csf-2015-2021/ https://pdcurejourney.org/landmarks/155-azathioprine-aza-pd-2020-2026/ https://pdcurejourney.org/landmarks/156-first-mitophagy-drugs-usp30-pink1-2023-2026/ https://pdcurejourney.org/landmarks/157-paraiso-prasinezumab-phase3-2025-2029/ https://pdcurejourney.org/landmarks/158-expdite-2-bemdaneprocel-phase3-2025-2027/ https://pdcurejourney.org/landmarks/159-beacon-biib122-lrrk2-carriers-2024-2027/ https://pdcurejourney.org/landmarks/16-gba-risk-factor-2009/ https://pdcurejourney.org/landmarks/160-regenerate-pd-ab1005-gdnf-gene-therapy-2024-2028/ https://pdcurejourney.org/landmarks/161-elldopa-levodopa-2004/ https://pdcurejourney.org/landmarks/162-tempo-rasagiline-2002-2009/ https://pdcurejourney.org/landmarks/163-calm-pd-real-pet-imaging-2002-2003/ https://pdcurejourney.org/landmarks/164-net-pd-futility-screens-2006-2007/ https://pdcurejourney.org/landmarks/165-proud-pramipexole-2013/ https://pdcurejourney.org/landmarks/166-leap-levodopa-2019/ https://pdcurejourney.org/landmarks/167-mds-diagnostic-criteria-2015/ https://pdcurejourney.org/landmarks/168-early-dbs-vanderbilt-pilot-2006-2020/ https://pdcurejourney.org/landmarks/169-precept-cep-1347-2007/ https://pdcurejourney.org/landmarks/17-floor-plate-dopamine-neurons-2011/ https://pdcurejourney.org/landmarks/170-tch346-2002-2006/ https://pdcurejourney.org/landmarks/171-mitoq-protect-2010/ https://pdcurejourney.org/landmarks/172-nopark-nicotinamide-riboside-2026/ https://pdcurejourney.org/landmarks/173-cnm-au8-repair-pd-2021/ https://pdcurejourney.org/landmarks/174-risvodetinib-c-abl-2025/ https://pdcurejourney.org/landmarks/175-spheramine-steps-2008-2011/ https://pdcurejourney.org/landmarks/176-nurr1-nr4a2-discovery-1997-2003/ https://pdcurejourney.org/landmarks/179-neurturin-autopsy-bartus-2011/ https://pdcurejourney.org/landmarks/18-gut-to-brain-spread-2019/ https://pdcurejourney.org/landmarks/180-fosgonimeton-shape-2022/ https://pdcurejourney.org/landmarks/181-intranasal-glutathione-2017/ https://pdcurejourney.org/landmarks/182-exidavnemab-exist-2024-2026/ https://pdcurejourney.org/landmarks/183-ub-312-vaccine-2022-2025/ https://pdcurejourney.org/landmarks/185-vtx3232-nlrp3-2024-2025/ https://pdcurejourney.org/landmarks/186-dapa-pd-dapansutrile-2026-2027/ https://pdcurejourney.org/landmarks/188-neu-411-neulark-2025-2027/ https://pdcurejourney.org/landmarks/189-semaglutide-and-next-glp1-trials-2019-2026/ https://pdcurejourney.org/landmarks/19-nalls-gwas-2019/ https://pdcurejourney.org/landmarks/190-large-pd-latino-gwas-2020-2021/ https://pdcurejourney.org/landmarks/191-uchl1-park5-1998/ https://pdcurejourney.org/landmarks/192-gigyf2-eif4g1-disputed-genes-2008-2011/ https://pdcurejourney.org/landmarks/193-lrp10-2018/ https://pdcurejourney.org/landmarks/194-lrrk2-asian-risk-variants-2007-2008/ https://pdcurejourney.org/landmarks/195-hla-region-gwas-2010/ https://pdcurejourney.org/landmarks/196-gcase-low-sporadic-pd-2012-2014/ https://pdcurejourney.org/landmarks/197-lrrk2-gcase-link-2019/ https://pdcurejourney.org/landmarks/198-lrrk2-activity-idiopathic-pd-2018/ https://pdcurejourney.org/landmarks/199-lrrk2-inhibitor-lung-primates-2015-2020/ https://pdcurejourney.org/landmarks/2-mptp-1983/ https://pdcurejourney.org/landmarks/20-glp1-story-2017-2025/ https://pdcurejourney.org/landmarks/200-dnl201-phase1-2022/ https://pdcurejourney.org/landmarks/201-snca-knockout-mice-viable-2000/ https://pdcurejourney.org/landmarks/202-beta2-agonists-lower-snca-2017/ https://pdcurejourney.org/landmarks/203-lag3-synuclein-receptor-2016/ https://pdcurejourney.org/landmarks/204-9e4-antibody-mice-2011/ https://pdcurejourney.org/landmarks/205-drosophila-synuclein-model-2000/ https://pdcurejourney.org/landmarks/206-pink1-parkin-fly-pathway-2006/ https://pdcurejourney.org/landmarks/207-complex-i-loss-ndufs2-mice-2021/ https://pdcurejourney.org/landmarks/208-terazosin-pgk1-glycolysis-2019/ https://pdcurejourney.org/landmarks/209-nadpark-phase1-2022/ https://pdcurejourney.org/landmarks/21-lewy-bodies-and-the-nigra-1912-1919/ https://pdcurejourney.org/landmarks/210-n-dose-nicotinamide-riboside-2025/ https://pdcurejourney.org/landmarks/211-c-abl-inactivates-parkin-2010/ https://pdcurejourney.org/landmarks/212-paris-zn746-pgc1a-2011/ https://pdcurejourney.org/landmarks/213-gdnf-discovery-1993/ https://pdcurejourney.org/landmarks/214-direct-reprogramming-dopamine-neurons-2011/ https://pdcurejourney.org/landmarks/215-graft-induced-dyskinesias-serotonin-2010/ https://pdcurejourney.org/landmarks/216-type-2-diabetes-parkinsons-risk-2011-2018/ https://pdcurejourney.org/landmarks/217-gut-microbiome-differs-in-pd-2015-2022/ https://pdcurejourney.org/landmarks/218-most-able-oral-semaglutide-2023-2027/ https://pdcurejourney.org/landmarks/219-radotinib-phase2-2021-2027/ https://pdcurejourney.org/landmarks/22-carlsson-dopamine-1957-1958/ https://pdcurejourney.org/landmarks/220-nose-pd-intranasal-insulin-glutathione-2022-2027/ https://pdcurejourney.org/landmarks/221-rbd-converts-to-synucleinopathy-1996-2019/ https://pdcurejourney.org/landmarks/222-mds-prodromal-criteria-2015-2019/ https://pdcurejourney.org/landmarks/223-blood-seed-amplification-2022-2023/ https://pdcurejourney.org/landmarks/224-free-water-mri-progression-marker-2009-2017/ https://pdcurejourney.org/landmarks/225-prevention-trials-prodromal-rbd-2026/ https://pdcurejourney.org/landmarks/226-critical-path-for-parkinsons-2015/ https://pdcurejourney.org/landmarks/227-lrrk2-loss-of-function-carriers-healthy-2020/ https://pdcurejourney.org/landmarks/228-rab29-activates-lrrk2-2013-2018/ https://pdcurejourney.org/landmarks/229-dnl151-biib122-phase1-1b-2021-2023/ https://pdcurejourney.org/landmarks/23-6ohda-model-and-first-grafts-1968-1979/ https://pdcurejourney.org/landmarks/230-lrrk2-first-structures-2020-2021/ https://pdcurejourney.org/landmarks/231-lrrk2-target-engagement-markers-2010-2023/ https://pdcurejourney.org/landmarks/232-lrp10-regulates-synuclein-secretion-2024/ https://pdcurejourney.org/landmarks/233-lysosomal-storage-gene-burden-2017/ https://pdcurejourney.org/landmarks/234-gt-02287-gcase-phase1b-2025-2026/ https://pdcurejourney.org/landmarks/235-bia-28-6156-activate-gba-carriers-2023-2026/ https://pdcurejourney.org/landmarks/236-single-prkn-copy-not-clear-risk-2020-2022/ https://pdcurejourney.org/landmarks/237-first-gwas-snca-mapt-and-24-loci-2009-2014/ https://pdcurejourney.org/landmarks/238-twin-study-low-heritability-1999/ https://pdcurejourney.org/landmarks/239-polg-mutations-parkinsonism-2004/ https://pdcurejourney.org/landmarks/24-ppmi-launch-2010/ https://pdcurejourney.org/landmarks/240-gch1-variants-parkinsons-risk-2014/ https://pdcurejourney.org/landmarks/241-basal-mitophagy-without-pink1-2018/ https://pdcurejourney.org/landmarks/242-ferroptosis-dopamine-neurons-2012-2016/ https://pdcurejourney.org/landmarks/243-parp1-parthanatos-synuclein-2018/ https://pdcurejourney.org/landmarks/244-too-little-synuclein-harms-neurons-2010-2018/ https://pdcurejourney.org/landmarks/245-braak-staging-critiques-2008-2009/ https://pdcurejourney.org/landmarks/246-lewy-body-extracts-mice-monkeys-2014/ https://pdcurejourney.org/landmarks/247-nr-safe-high-dose-nicotinamide-riboside-2022-2023/ https://pdcurejourney.org/landmarks/248-terazosin-randomised-pilot-2019-2021/ https://pdcurejourney.org/landmarks/249-type-2-diabetes-mendelian-randomisation-2021/ https://pdcurejourney.org/landmarks/25-pesticides-and-solvents-2011/ https://pdcurejourney.org/landmarks/250-ret-agonists-small-gdnf-mimics-2017-2021/ https://pdcurejourney.org/landmarks/251-pdgf-bb-intraventricular-phase-1-2009-2015/ https://pdcurejourney.org/landmarks/252-aav2-gad-sham-controlled-phase-2-2008-2025/ https://pdcurejourney.org/landmarks/253-mri-guided-convection-enhanced-delivery-2005-2011/ https://pdcurejourney.org/landmarks/254-aav-php-b-fails-in-primates-ly6a-2018-2019/ https://pdcurejourney.org/landmarks/255-human-tfr1-aav-capsids-2024/ https://pdcurejourney.org/landmarks/256-nusinersen-intrathecal-antisense-2016/ https://pdcurejourney.org/landmarks/257-lewy-bodies-in-gut-nerve-plexuses-1988/ https://pdcurejourney.org/landmarks/258-constipation-precedes-parkinsons-2001/ https://pdcurejourney.org/landmarks/259-synuclein-gut-to-brain-in-rats-2014/ https://pdcurejourney.org/landmarks/26-coq10-qe3-2014/ https://pdcurejourney.org/landmarks/260-ent-01-squalamine-karmet-2018-2021/ https://pdcurejourney.org/landmarks/261-gut-biopsy-synuclein-poor-specificity-2012-2016/ https://pdcurejourney.org/landmarks/262-effaced-pd-warsaw-fmt-2022-2026/ https://pdcurejourney.org/landmarks/263-soroka-fmt-pilot-2015-2020/ https://pdcurejourney.org/landmarks/264-ibuprofen-nsaids-lower-parkinsons-risk-2003-2011/ https://pdcurejourney.org/landmarks/265-pet-microglial-activation-in-living-patients-2006/ https://pdcurejourney.org/landmarks/266-gut-infection-pink1-knockout-mice-2019/ https://pdcurejourney.org/landmarks/267-nigral-ventrolateral-tier-loss-1991/ https://pdcurejourney.org/landmarks/268-vmat2-dopamine-storage-2007-2014/ https://pdcurejourney.org/landmarks/269-cytosolic-dopamine-calcium-2009/ https://pdcurejourney.org/landmarks/27-synuclein-fibril-structures-2018-2022/ https://pdcurejourney.org/landmarks/270-yeast-synuclein-models-2003-2006/ https://pdcurejourney.org/landmarks/271-knockout-mice-keep-dopamine-neurons-2003-2007/ https://pdcurejourney.org/landmarks/272-isogenic-ipsc-soldner-2011/ https://pdcurejourney.org/landmarks/273-iscore-pd-isogenic-collection-2024-2026/ https://pdcurejourney.org/landmarks/274-fluorodopa-pet-1983/ https://pdcurejourney.org/landmarks/275-csf-total-synuclein-too-overlapping-2011-2013/ https://pdcurejourney.org/landmarks/276-neuromelanin-mri-nigrosome-sign-2006-2014/ https://pdcurejourney.org/landmarks/277-parkinson-study-group-founded-1985/ https://pdcurejourney.org/landmarks/278-pd-generation-genetic-testing-2019-2024/ https://pdcurejourney.org/landmarks/279-amp-pd-data-platform-2018/ https://pdcurejourney.org/landmarks/28-biological-definitions-2024/ https://pdcurejourney.org/landmarks/280-fox-insight-online-cohort-2017/ https://pdcurejourney.org/landmarks/281-naps-prodromal-synucleinopathy-consortium-2018-2028/ https://pdcurejourney.org/landmarks/282-idebenone-irbd-ruijin-2020-2026/ https://pdcurejourney.org/landmarks/283-placebo-dopamine-release-2001/ https://pdcurejourney.org/landmarks/284-hoehn-yahr-staging-scale-1967/ https://pdcurejourney.org/landmarks/285-levodopa-becomes-standard-treatment-1961-1967/ https://pdcurejourney.org/landmarks/286-smell-loss-predicts-parkinsons-2004-2008/ https://pdcurejourney.org/landmarks/287-aln-snca-sirna-2025-2029/ https://pdcurejourney.org/landmarks/288-ly3962681-sirna-2024-2030/ https://pdcurejourney.org/landmarks/289-ion464-biib101-snca-antisense-2022-2027/ https://pdcurejourney.org/landmarks/29-synuclein-lowering-drugs-2023-2026/ https://pdcurejourney.org/landmarks/290-ro7568282-nlrp3-tarbela-pd-2026-2028/ https://pdcurejourney.org/landmarks/291-vent-02-nlrp3-phase-1b-2025/ https://pdcurejourney.org/landmarks/292-tj0113-mitophagy-2024-2028/ https://pdcurejourney.org/landmarks/293-bhv-8000-tyk2-jak1-2025-2027/ https://pdcurejourney.org/landmarks/294-tb006-galectin-3-antibody-2025-2026/ https://pdcurejourney.org/landmarks/296-hydroxychloroquine-hcq-pd-ottawa-2025-2027/ https://pdcurejourney.org/landmarks/297-nouvneu001-ipsc-dopamine-cells-2024-2026/ https://pdcurejourney.org/landmarks/298-china-ipsc-dopamine-cell-trial-wave-2025-2026/ https://pdcurejourney.org/landmarks/299-rndp-001-kenai-replace-2025-2027/ https://pdcurejourney.org/landmarks/3-fetal-transplants-1987-2025/ https://pdcurejourney.org/landmarks/30-ipsc-neurons-in-monkeys-2017/ https://pdcurejourney.org/landmarks/300-kyoto-ipsc-dopamine-cells-phase-1-2-2018-2025/ https://pdcurejourney.org/landmarks/301-mgh-autologous-ipsc-dopamine-phase-1-2025-2028/ https://pdcurejourney.org/landmarks/302-vgn-r08b-gba1-gene-therapy-2026-2027/ https://pdcurejourney.org/landmarks/303-cap-003-capsida-iv-gba1-gene-therapy-2025-2026/ https://pdcurejourney.org/landmarks/304-aav9-crosses-blood-brain-barrier-foust-2009/ https://pdcurejourney.org/landmarks/305-voyager-vy-aadc-phase-1b-restore-1-2017-2021/ https://pdcurejourney.org/landmarks/306-voyager-vcap-102-alpl-capsid-2025/ https://pdcurejourney.org/landmarks/307-grf6021-plasma-fraction-2018-2021/ https://pdcurejourney.org/landmarks/308-akst4290-ccr3-teal-2020-2021/ https://pdcurejourney.org/landmarks/309-pt320-sustained-release-exenatide-2020-2021/ https://pdcurejourney.org/landmarks/31-a53t-synuclein-mice-2002/ https://pdcurejourney.org/landmarks/310-stockholm-exenatide-fdg-pet-2020-2025/ https://pdcurejourney.org/landmarks/311-molecular-hydrogen-trials-2013-2021/ https://pdcurejourney.org/landmarks/312-epi-589-phase2a-2016-2019/ https://pdcurejourney.org/landmarks/313-fasudil-rock-pd-2023-2026/ https://pdcurejourney.org/landmarks/314-lithium-trials-2019-2026/ https://pdcurejourney.org/landmarks/315-nac-monti-trials-2014-2027/ https://pdcurejourney.org/landmarks/316-australian-parkinsons-mission-apm001-2020-2026/ https://pdcurejourney.org/landmarks/317-freed-sham-fetal-grafts-2001/ https://pdcurejourney.org/landmarks/318-olanow-sham-fetal-grafts-2003/ https://pdcurejourney.org/landmarks/319-transeuro-fetal-grafts-2010-2026/ https://pdcurejourney.org/landmarks/32-ipsc-reprogramming-2006-2007/ https://pdcurejourney.org/landmarks/320-ambitious-ambroxol-gba-pd-2022-2026/ https://pdcurejourney.org/landmarks/321-aspro-pd-ambroxol-phase3-2025-2029/ https://pdcurejourney.org/landmarks/322-nilotinib-nilo-pd-georgetown-2017-2021/ https://pdcurejourney.org/landmarks/323-vodobatinib-proseek-2019-2026/ https://pdcurejourney.org/landmarks/324-pd01a-affiris-synuclein-vaccine-2012-2020/ https://pdcurejourney.org/landmarks/325-aci-7104-vacsyn-phase2-2023-2028/ https://pdcurejourney.org/landmarks/326-prasinezumab-gba-precode-2025-2030/ https://pdcurejourney.org/landmarks/327-htra2-omi-park13-2005-2021/ https://pdcurejourney.org/landmarks/328-dnajc13-tmem230-disputed-genes-2014-2021/ https://pdcurejourney.org/landmarks/329-atp10b-lysosomal-lipid-flippase-2020-2025/ https://pdcurejourney.org/landmarks/33-dj1-gene-2003/ https://pdcurejourney.org/landmarks/330-psap-saposin-d-variants-2020-2021/ https://pdcurejourney.org/landmarks/331-dctn1-perry-syndrome-2009/ https://pdcurejourney.org/landmarks/332-age-at-onset-and-progression-gwas-2019-2023/ https://pdcurejourney.org/landmarks/333-polygenic-risk-scores-2015-2019/ https://pdcurejourney.org/landmarks/334-snca-rep1-promoter-risk-2006/ https://pdcurejourney.org/landmarks/335-snca-duplications-penetrance-2004-2009/ https://pdcurejourney.org/landmarks/336-synuclein-t-cells-highest-near-diagnosis-2020/ https://pdcurejourney.org/landmarks/338-camp-lejeune-tce-cohort-2023/ https://pdcurejourney.org/landmarks/339-manganese-parkinsonism-welders-miners-1967-2013/ https://pdcurejourney.org/landmarks/34-synuclein-snare-chaperone-2010/ https://pdcurejourney.org/landmarks/340-dieldrin-organochlorines-in-parkinsons-brains-1994-2009/ https://pdcurejourney.org/landmarks/341-gbd-2016-parkinsons-burden-2018/ https://pdcurejourney.org/landmarks/342-locus-coeruleus-loss-parkinsons-1992-2007/ https://pdcurejourney.org/landmarks/343-calbindin-neurons-spared-ventral-tegmental-1990-1992/ https://pdcurejourney.org/landmarks/344-necroptosis-in-parkinsons-models-2018-2020/ https://pdcurejourney.org/landmarks/345-datscan-eu-and-fda-approvals-2000-2011/ https://pdcurejourney.org/landmarks/346-fda-letter-of-support-synuclein-saa-2024/ https://pdcurejourney.org/landmarks/347-mclean-brigham-autologous-ipsc-dopamine-phase-1-2024-2028/ https://pdcurejourney.org/landmarks/348-ucsd-ct1-dap001-ipsc-dopamine-phase-1-2-2024-2028/ https://pdcurejourney.org/landmarks/349-finnish-fmt-trial-scheperjans-2020-2024/ https://pdcurejourney.org/landmarks/35-gcase-synuclein-loop-2011/ https://pdcurejourney.org/landmarks/350-single-pink1-copy-not-clear-risk-2017-2022/ https://pdcurejourney.org/landmarks/352-kolf2-1j-reference-ipsc-line-2022/ https://pdcurejourney.org/landmarks/353-foundin-pd-ipsc-dopamine-neuron-omics-2023/ https://pdcurejourney.org/landmarks/355-ppm1h-reverses-lrrk2-rab-phosphorylation-2019/ https://pdcurejourney.org/landmarks/356-amchepry-japan-conditional-approval-2026/ https://pdcurejourney.org/landmarks/36-vps35-retromer-2011/ https://pdcurejourney.org/landmarks/37-lrrk2-rab-proteins-2016/ https://pdcurejourney.org/landmarks/38-t-cells-synuclein-2017/ https://pdcurejourney.org/landmarks/39-gdnf-gene-therapy-2003-2026/ https://pdcurejourney.org/landmarks/4-snca-gene-1997/ https://pdcurejourney.org/landmarks/40-ambroxol-2020-2026/ https://pdcurejourney.org/landmarks/41-aav-synuclein-rat-and-marmoset-models-2002-2003/ https://pdcurejourney.org/landmarks/42-mitopark-mouse-2007/ https://pdcurejourney.org/landmarks/43-pff-seeding-models-2011-2012/ https://pdcurejourney.org/landmarks/44-snca-point-mutations-1998-2013/ https://pdcurejourney.org/landmarks/45-atp13a2-kufor-rakeb-2006/ https://pdcurejourney.org/landmarks/46-lrrk2-g2019s-penetrance-2008/ https://pdcurejourney.org/landmarks/47-patient-ipsc-dopamine-neurons-2011/ https://pdcurejourney.org/landmarks/48-midbrain-organoids-2016/ https://pdcurejourney.org/landmarks/49-snca-enhancer-risk-variant-2016/ https://pdcurejourney.org/landmarks/5-synuclein-in-lewy-bodies-1997/ https://pdcurejourney.org/landmarks/50-juvenile-parkinsonism-dnajc6-synj1-2012-2013/ https://pdcurejourney.org/landmarks/51-synuclein-fibril-seeding-2012/ https://pdcurejourney.org/landmarks/52-microglia-in-nigra-1988/ https://pdcurejourney.org/landmarks/53-toxic-astrocytes-2017-2018/ https://pdcurejourney.org/landmarks/54-parkin-pink1-sting-retracted-2018/ https://pdcurejourney.org/landmarks/55-nlrp3-inflammasome-2018/ https://pdcurejourney.org/landmarks/56-gut-microbiota-mice-2016/ https://pdcurejourney.org/landmarks/57-cav13-calcium-pacemaking-2007/ https://pdcurejourney.org/landmarks/58-dopamine-oxidation-2017/ https://pdcurejourney.org/landmarks/59-chaperone-mediated-autophagy-2004/ https://pdcurejourney.org/landmarks/6-braak-staging-2003/ https://pdcurejourney.org/landmarks/60-synuclein-strains-2015/ https://pdcurejourney.org/landmarks/61-datatop-deprenyl-1989-1993/ https://pdcurejourney.org/landmarks/62-adagio-rasagiline-2009/ https://pdcurejourney.org/landmarks/63-prasinezumab-pasadena-padova-2022-2026/ https://pdcurejourney.org/landmarks/64-spark-cinpanemab-2021-2022/ https://pdcurejourney.org/landmarks/65-orchestra-minzasolmin-2024/ https://pdcurejourney.org/landmarks/66-sure-pd3-inosine-2021/ https://pdcurejourney.org/landmarks/67-fairpark-ii-deferiprone-2022/ https://pdcurejourney.org/landmarks/68-nilotinib-c-abl-2014-2024/ https://pdcurejourney.org/landmarks/69-gba-drugs-venglustat-bia-2023-2026/ https://pdcurejourney.org/landmarks/7-lrrk2-2004/ https://pdcurejourney.org/landmarks/70-net-pd-creatine-2015/ https://pdcurejourney.org/landmarks/71-rt-quic-and-pmca-origins-2016-2020/ https://pdcurejourney.org/landmarks/72-lund-hesc-dopamine-recipe-2012-2017/ https://pdcurejourney.org/landmarks/73-autologous-ipsc-graft-2020/ https://pdcurejourney.org/landmarks/74-stem-pd-trial-2023-2026/ https://pdcurejourney.org/landmarks/75-astrocyte-reprogramming-2020-2023/ https://pdcurejourney.org/landmarks/76-aspen-autologous-aspiro-2024-2026/ https://pdcurejourney.org/landmarks/77-michael-j-fox-foundation-2000/ https://pdcurejourney.org/landmarks/78-asap-and-gp2-2019-2021/ https://pdcurejourney.org/landmarks/79-dat-imaging-regulatory-qualification-2015-2018/ https://pdcurejourney.org/landmarks/8-lewy-pathology-in-grafts-2008/ https://pdcurejourney.org/landmarks/80-ejs-act-pd-platform-trial-2025/ https://pdcurejourney.org/landmarks/81-mtdna-deletions-nigral-neurons-2006/ https://pdcurejourney.org/landmarks/82-smoking-and-coffee-protective-association-2000-2023/ https://pdcurejourney.org/landmarks/83-vagotomy-and-appendix-studies-2015-2018/ https://pdcurejourney.org/landmarks/84-ibd-anti-tnf-and-lrrk2-2018/ https://pdcurejourney.org/landmarks/85-head-injury-and-parkinsons-2018/ https://pdcurejourney.org/landmarks/86-gba-mutation-severity-2015-2016/ https://pdcurejourney.org/landmarks/87-tmem175-lysosome-channel-2014-2026/ https://pdcurejourney.org/landmarks/88-rab32-ser71arg-2024/ https://pdcurejourney.org/landmarks/89-mendelian-randomisation-urate-bmi-2014-2021/ https://pdcurejourney.org/landmarks/9-seed-amplification-assay-2023/ https://pdcurejourney.org/landmarks/90-chchd2-park22-2015/ https://pdcurejourney.org/landmarks/91-lewy-body-lipids-organelles-2019/ https://pdcurejourney.org/landmarks/92-synuclein-oligomers-toxic-2011/ https://pdcurejourney.org/landmarks/93-axon-arbor-energy-cost-2013/ https://pdcurejourney.org/landmarks/94-synuclein-ser129-phosphorylation-2002/ https://pdcurejourney.org/landmarks/95-synuclein-extracellular-vesicles-2010/ https://pdcurejourney.org/landmarks/96-lrrk2-lysosome-damage-response-2018/ https://pdcurejourney.org/landmarks/97-striatal-terminals-lost-first-2013/ https://pdcurejourney.org/landmarks/98-glial-activation-midbrain-single-cell-2022/ https://pdcurejourney.org/landmarks/99-vulnerable-dopamine-neuron-subtype-2022/ https://pdcurejourney.org/privacy/ https://pdcurejourney.org/report-an-error/ https://pdcurejourney.org/report-an-error/problem/ https://pdcurejourney.org/report-an-error/thanks/ https://pdcurejourney.org/research/ https://pdcurejourney.org/research/changes/ https://pdcurejourney.org/research/coverage/ https://pdcurejourney.org/research/data/ https://pdcurejourney.org/research/dead-ends/ https://pdcurejourney.org/research/lanes/ https://pdcurejourney.org/research/lanes/biomarkers/ https://pdcurejourney.org/research/lanes/cell-replacement/ https://pdcurejourney.org/research/lanes/cell-survival/ https://pdcurejourney.org/research/lanes/environment/ https://pdcurejourney.org/research/lanes/foundations/ https://pdcurejourney.org/research/lanes/gene-delivery/ https://pdcurejourney.org/research/lanes/genetics/ https://pdcurejourney.org/research/lanes/growth-factors/ https://pdcurejourney.org/research/lanes/gut-brain/ https://pdcurejourney.org/research/lanes/inflammation/ https://pdcurejourney.org/research/lanes/infrastructure/ https://pdcurejourney.org/research/lanes/lrrk2/ https://pdcurejourney.org/research/lanes/lysosome-gba/ https://pdcurejourney.org/research/lanes/metabolic-repurposing/ https://pdcurejourney.org/research/lanes/mitochondria/ https://pdcurejourney.org/research/lanes/models/ https://pdcurejourney.org/research/lanes/oxidative-stress/ https://pdcurejourney.org/research/lanes/synuclein-dosage/ https://pdcurejourney.org/research/lanes/synuclein-spread/ https://pdcurejourney.org/research/lanes/trial-methods/ https://pdcurejourney.org/research/lanes/vulnerability/ https://pdcurejourney.org/research/map/ https://pdcurejourney.org/research/readouts/ https://pdcurejourney.org/what-failed/ https://pdcurejourney.org/what-is-a-cure/